Clinical

Dataset Information

0

CAPEOX and bevacizumab combined with or without sintilimab (recombinant fully human anti-programmed death receptor 1 monoclonal antibody) in the first-line conversion therapy for initial unresectable microsatellite stable colorectal cancer liver metastases with RAS mutation or right-sided primary: A randomized, open-label, multi-center phase II study


ABSTRACT: Interventions: Group A:Bevacizumab 7.5mg/kg, administered on the first day, intravenous injection; oxaliplatin 130mg/m^2 administered on the first day, intravenous injection; capecitabine 1g/m^2 twice a day, orally, continuously 14 days, 1 week off, 3 weeks for a cycle;Group B:Bevacizumab 7.5mg/kg, administered on the first day, intravenous injection; oxaliplatin 130mg/m^2 administered on the first day, intravenous injection; capecitabine 1g/m^2 twice a day, orally, continuously 14 days, 1 week off; sintilimab 200mg, administered on the first day, intravenous injection,3 weeks for a cycle. Primary outcome(s): objective response rate Study Design: Parallel

DISEASE(S): Colorectal Cancer Liver Metastases

PROVIDER: 88881 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2619416 | ecrin-mdr-crc
| 2618906 | ecrin-mdr-crc
| 2618974 | ecrin-mdr-crc
2022-01-06 | PXD030757 | Pride
| 2622491 | ecrin-mdr-crc
2005-09-29 | E-MIMR-38 | biostudies-arrayexpress
| 2647236 | ecrin-mdr-crc
2010-07-29 | E-GEOD-22553 | biostudies-arrayexpress
| 2622561 | ecrin-mdr-crc
2023-01-11 | GSE221003 | GEO